A5051276757- HIV Research and Treatment
- Immune Cell Function and Interaction
- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- Cytomegalovirus and herpesvirus research
- HIV-related health complications and treatments
- T-cell and B-cell Immunology
- Viral-associated cancers and disorders
- Blood groups and transfusion
- Ubiquitin and proteasome pathways
- Protein Degradation and Inhibitors
- Reproductive System and Pregnancy
- Sex work and related issues
- Renal Transplantation Outcomes and Treatments
- Cancer-related Molecular Pathways
- Lymphoma Diagnosis and Treatment
- HIV, Drug Use, Sexual Risk
University of California, San Francisco
2017-2023
City College of San Francisco
2017
Louisiana State University Agricultural Center
2002
Background It is unknown if extremely early initiation of antiretroviral therapy (ART) may lead to long-term ART-free HIV remission or cure. As a result, we studied 2 individuals recruited from pre-exposure prophylaxis (PrEP) program who started prophylactic ART an estimated 10 days (Participant A; 54-year-old male) and 12 B; 31-year-old after infection with peak plasma RNA 220 copies/mL 3,343 copies/mL, respectively. Extensive testing blood tissue for persistence was performed, PrEP...
HIV-1-infected cells persist indefinitely despite the use of combination antiretroviral therapy (ART), and novel therapeutic strategies to target purge residual infected in individuals on ART are urgently needed. Here, we demonstrate that CD4+ T cell-associated HIV-1 RNA is often highly enriched expressing CD30, this marker considerably contribute total pool transcriptionally active lymphocytes suppressive ART. Using situ hybridization studies, show co-localization CD30 with transcriptional...
Pharmacologic inhibition of the mammalian target rapamycin (mTOR) in setting renal transplantation has previously been associated with lower human immunodeficiency virus 1 (HIV-1) DNA burden, and vitro studies suggest that mTOR may lead to HIV transcriptional silencing. Because prospective clinical trials are lacking, we conducted an open-label, single-arm study determine impact broad inhibitor, everolimus, on residual gene expression profiles, immune responses HIV-infected adult solid organ...
Persistent tissue reservoirs of HIV present a major barrier to cure. Defining subsets infected cells in tissues is focus cure research. Herein, we describe novel multiplexed situ hybridization (ISH) (RNAscope) protocol detect HIV-DNA (vDNA) and HIV-RNA (vRNA) formalin-fixed paraffin-embedded (FFPE) human combination with immunofluorescence (IF) phenotyping the cells. We show that IF ISH (mIFISH) suitable for quantitative assessment vRNA vDNA multiparameter allows precise identification...
Prior genomewide association studies have identified variation in major histocompatibility complex (MHC) class I alleles and C-C chemokine receptor type 5 gene (CCR5Δ32) as genetic predictors of viral control, especially 'elite' controllers, individuals who remain virally suppressed the absence therapy.Cross-sectional study.We analyzed custom whole exome sequencing direct human leukocyte antigen (HLA) typing from 202 antiretroviral therapy (ART)-suppressed HIV+ noncontrollers relation to...
Abstract Background Elite controllers (EC), a small subset of the HIV-positive population (< 1%), suppress HIV viremia below limit quantification clinical viral load assays in absence antiretroviral therapy (ART). However, there is paucity longitudinal data detailing and immune dynamics or reservoir seeding during acute infection individuals that go on to become Controllers. Case presentation In this report, we describe case 42 year old woman diagnosed who rapidly permanently suppressed...
The major barrier to an HIV cure is the reservoir: latently-infected cells that persist despite effective antiretroviral therapy (ART). There have been few cohort-based studies evaluating host genomic or transcriptomic predictors of reservoir. We performed RNA sequencing and reservoir quantification (total DNA [tDNA], unspliced [usRNA], intact DNA) from peripheral CD4+ T 191 ART-suppressed people with (PWH). After adjusting for nadir count, timing ART initiation, genetic ancestry, we...
The major barrier to an HIV cure is the persistence of infected cells that evade host immune surveillance despite effective antiretroviral therapy (ART). Most prior genetic studies have focused on identifying DNA polymorphisms (e.g., CCR5Δ32 , MHC class I alleles) associated with viral load among untreated "elite controllers" (~1% HIV+ individuals who are able control virus without ART). However, there been few evaluating predictors for majority people living (PLWH) ART. We performed RNA...
Abstract Objective Prior genomewide association studies have identified variation in MHC Class I alleles and CCR5 Δ 32 as genetic predictors of viral control, especially “elite” controllers, individuals who remain virally suppressed the absence therapy. Design Cross-sectional study. Methods We analyzed custom whole exome sequencing direct HLA typing from 202 ART-suppressed HIV+ non-controllers relation to four measures peripheral CD4+ T cell reservoir: HIV intact DNA, total (t)DNA, unspliced...
After publication of the original article [1], we were notified in Table 1 a column should be removed.